Nymox Pharmaceutical Corporation
NYMXF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $74 | $70 | $1,403 | $830 |
| Short-Term Investments | $0 | $0 | $0 | $0 |
| Receivables | $27 | $11 | $10 | $13 |
| Inventory | $0 | $0 | $0 | $34 |
| Other Curr. Assets | $552 | $544 | $44 | $160 |
| Total Curr. Assets | $653 | $625 | $1,457 | $1,037 |
| Property Plant & Equip (Net) | $1 | $2 | $168 | $406 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $589 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $0 | $0 | $0 | $0 |
| Total NC Assets | $1 | $2 | $168 | $995 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $654 | $627 | $1,625 | $2,032 |
| Liabilities | – | – | – | – |
| Payables | $4,115 | $3,023 | $1,697 | $1,273 |
| Short-Term Debt | $0 | $750 | $173 | $228 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $0 | $0 | $0 |
| Other Curr. Liab. | $3,314 | $27 | $237 | $285 |
| Total Curr. Liab. | $7,429 | $3,800 | $2,107 | $1,786 |
| LT Debt | $0 | $0 | $0 | $163 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $0 | $0 | $0 | $0 |
| Total NC Liab. | $0 | $0 | $0 | $163 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $0 | $0 | $173 | $391 |
| Total Liabilities | $7,429 | $3,800 | $2,107 | $1,949 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $177,687 | $173,816 | $171,671 | $165,061 |
| Retained Earnings | -$212,474 | -$207,982 | -$199,138 | -$192,562 |
| AOCI | $0 | $0 | $0 | $0 |
| Other Equity | $28,012 | $30,993 | $26,985 | $27,584 |
| Total Equity | -$6,775 | -$3,173 | -$482 | $83 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $654 | $627 | $1,625 | $2,032 |
| Net Debt | -$74 | $680 | -$1,230 | -$439 |